Ketamine Dropout Rates: The Case for Troche Optimization

Why Patients Stop—And Why It Matters

A new analysis published in Psychiatric Times (April 2026) is drawing attention to a problem that often goes underdiscussed in ketamine treatment circles: a meaningful number of patients discontinue NMDA receptor antagonist therapy not because it fails to work, but because the side effects become unmanageable. The piece, written for clinicians treating treatment-resistant depression with NMDA antagonists, urges faster, data-driven decision-making: optimize doses earlier, switch formulations sooner when tolerance is poor, and track both PHQ-9 scores and adverse event logs on a session-by-session basis.

For the troche community specifically, this framing is clarifying. Dropout is not just a clinical inconvenience—it represents a failure to reach remission for a patient population that has already exhausted other options. Understanding why patients stop, and which delivery formats are most associated with early discontinuation, is directly actionable information.

Side Effect Profiles Vary Significantly Across Delivery Methods

The article compares IV ketamine, intranasal esketamine (Spravato), and other formulations across several tolerability dimensions. The most commonly reported adverse effects across all NMDA antagonists include dissociation, dizziness, nausea, elevated blood pressure, and in some patients, anxiety or perceptual disturbances. Discontinuation rates, however, are not uniform.

IV infusion carries the highest plasma concentration peaks—which is partly why it works quickly for acute suicidality—but those same peaks drive more intense dissociative episodes and cardiovascular fluctuations. Esketamine nasal spray sits in a middle range: more titrateable than IV, but still clinic-administered, making adjustments logistically cumbersome. Both formats require on-site monitoring and transportation restrictions for hours after each session, which creates its own dropout vector: patients who can't sustain the scheduling burden stop showing up before they've completed an adequate trial.

Compounded ketamine troches occupy a genuinely different position in this landscape. Because they're absorbed transmucosally at lower peak plasma levels than IV, the dissociative intensity is typically milder—and because they're taken at home, session logistics don't require a clinic visit. This combination doesn't eliminate side effects, but it does change their character and the patient's ability to manage them within their own environment. Nausea remains a relevant concern for some troche users, particularly at higher doses or when swallowed rather than held sublingually. Blood pressure elevation is still worth monitoring. But the absence of a sharp IV-style peak meaningfully flattens the tolerability curve for many patients.

The Argument for Systematic Tracking

One of the most practically useful recommendations in the Psychiatric Times piece is deceptively simple: track outcomes and side effects on every session, not just at intake and follow-up. The authors advocate for regular PHQ-9 monitoring so that clinicians can identify partial responders early and adjust protocols before a patient gives up. The same logic applies to adverse event tracking—if a patient reports dizziness every session for six weeks but no one documents it systematically, there's no data to justify a dose reduction or formulation switch.

For troche users in home-based programs, this places a practical responsibility on both patient and provider. Keeping a simple session log—dose taken, duration held sublingually, time of day, side effects experienced, and a quick mood rating—gives your prescriber the raw material to make informed adjustments. Many telehealth ketamine providers now supply structured check-in forms for exactly this reason. If yours doesn't, ask for one or create your own. The difference between a 200mg troche and a 300mg troche in terms of tolerability can be substantial; without a log, that adjustment never gets made.

The article also flags the risk of premature switching—moving from one NMDA antagonist to another before an adequate trial is complete—as a separate contributor to poor outcomes. For troches, an adequate trial is generally considered to be six to eight sessions over three to four weeks at a therapeutic dose. Stopping after two or three sessions because of early side effects, before the dose has been optimized, misses the window where most clinically meaningful response occurs.

Practical Steps if You're Struggling With Side Effects

If the new tolerability data resonates with your own experience, here's what's actionable right now. First, identify whether your side effects are dose-related or delivery-related. Nausea and dizziness that appear consistently suggest you may be absorbing too much too quickly—try holding the troche longer before spitting rather than swallowing the dissolved material. Second, time of day matters more than many patients expect: evening dosing tends to reduce next-day functional impairment, while morning dosing works better for some people's dissociative tolerance windows. Third, if blood pressure elevation is a concern, your prescriber should be reviewing your cardiovascular baseline and potentially adjusting the dose ceiling accordingly.

What the Psychiatric Times analysis ultimately reinforces is that NMDA antagonist therapy—including troche-based ketamine—is not a one-size protocol. The patients most likely to discontinue prematurely are those whose side effect experience isn't being actively managed and communicated. The patients most likely to reach remission are those whose providers are tracking data, adjusting doses, and treating tolerability as part of the clinical outcome—not a secondary concern.